UCB Additional Bimzelx post-hoc analyses in HS
Additional post-hoc analyses for bimekizumab in its Ph 3 trials for hidradenitis suppurativa show sustained improvements in skin pain and draining tunnel count. Beyond the earlier reported HiSCR endpoints, bime confirms its clinical relevance across the spectrum. We maintain a €110 TP and adopt an Accumulate rating (previously Buy).UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.